Bisphosphonate's Effect on Tongue Mucosa: An Experimental Electron Microscopy Study

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2020 Jan 30

PMID 31991568

Citations 3

Authors

Theodora Papamitsou

Antonios Morsi-Yeroyannis

Anastasios Papanastasiou

Nikolaos Bakalopoulos

Eva-Maria Dietrich

Sofia Karachrysafi

Alexandros Toskas

Evangelia Mareti

Anastasia Morsi-Yeroyanni

Antonia Sioga

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Bisphosphonates (BPs) are selective inhibitors of osteoclasts, used for the treatment of bone disorders. The objective of this study is to investigate the possible effects of BPs on the tongue's mucosa.

Materials And Methods: Specimens of the tongue of 20 female 12-month old Wistar rats were taken. Ten were used as control group, while in the remaining alendronate (Fosamax, Merck) was administered per os from 13 weeks. Observation of the harvested samples was made by Transmission Electron Microscopy (TEM).

Results: In the experimental group, focal alterations were observed to various extent in all specimens. The basement membrane was intact. Furthermore, an increase at the intercellular space was observed, predominantly at the middle layer, and the desmosomes were disorganized. In the lamina propria focal edema was observed.

Conclusions: Investigation on the effect of BPs on the tongue's mucosa through TEM hasn't been documented in the past. According to our results, BPs seem to cause mild mucosal lesions on the tongue.

Citing Articles

Bisphosphonate's effect on the tongue in adult male albino rats and the possible protective role of rutin: light and scanning electron microscopic study.

El-Ghazouly D, Yassien R Anat Cell Biol. 2024; 57(1):129-142.

PMID: 38360060 PMC: 10968185. DOI: 10.5115/acb.23.230.

Bisphosphonate affects the behavioral responses to HCl by disrupting farnesyl diphosphate synthase in mouse taste bud and tongue epithelial cells.

Oike A, Iwata S, Hirayama A, Ono Y, Nagasato Y, Kawabata Y Sci Rep. 2022; 12(1):21246.

PMID: 36481783 PMC: 9732047. DOI: 10.1038/s41598-022-25755-5.

Oral bisphosphonates: Adverse effects on the oral mucosa not related to the jaw bones. A scoping review.

Psimma C, Psimma Z, Willems H, Kluter W, van der Maarel-Wierink C Gerodontology. 2021; 39(4):330-338.

PMID: 34725854 PMC: 9787882. DOI: 10.1111/ger.12590.

References

Kharazmi M, Sjoqvist K, Rizk M, Warfvinge G . Oral ulcer associated with alendronate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(6):e11-3. DOI: 10.1016/j.tripleo.2010.04.035. View

Ng S, Chow L, Zed C . Oral erosive mucositis associated with improper administration of a drug. J Can Dent Assoc. 2010; 76:a156. View

Ponte Fernandez N, Estefania Fresco R, Urizar J . Bisphosphonates and oral pathology I. General and preventive aspects. Med Oral Patol Oral Cir Bucal. 2006; 11(5):E396-400. View

Dhillon S, Lyseng-Williamson K . Zoledronic acid : a review of its use in the management of bone metastases of malignancy. Drugs. 2008; 68(4):507-34. DOI: 10.2165/00003495-200868040-00010. View

Jeal W, Barradell L, McTavish D . Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs. 1997; 53(3):415-34. DOI: 10.2165/00003495-199753030-00006. View

Porras A, Holland S, Gertz B . Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999; 36(5):315-28. DOI: 10.2165/00003088-199936050-00002. View

Oh Y, Yoon C, Park S . Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies. World J Gastroenterol. 2012; 18(40):5779-88. PMC: 3484348. DOI: 10.3748/wjg.v18.i40.5779. View

Sharpe M, Noble S, Spencer C . Alendronate: an update of its use in osteoporosis. Drugs. 2001; 61(7):999-1039. DOI: 10.2165/00003495-200161070-00010. View

Serrano A, Begona L, Anitua E, Cobos R, Orive G . Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013; 29(12):1005-14. DOI: 10.3109/09513590.2013.813468. View

10.

Papapetrou P . Bisphosphonate-associated adverse events. Hormones (Athens). 2009; 8(2):96-110. DOI: 10.14310/horm.2002.1226. View

11.

Body J, Bergmann P, Boonen S, Devogelaer J, Gielen E, Goemaere S . Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int. 2012; 23 Suppl 1:S1-23. PMC: 3273686. DOI: 10.1007/s00198-011-1891-8. View

12.

Treister N, Richardson P, Schlossman R, Miller K, Woo S . Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105(6):e1-4. DOI: 10.1016/j.tripleo.2008.02.010. View

13.

Wright E, Schofield P, Molokhia M . Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis. BMJ Open. 2015; 5(12):e007133. PMC: 4680000. DOI: 10.1136/bmjopen-2014-007133. View

14.

Oliveira T, Bradaschia-Correa V, Castro J, Simoes A, Arana-Chavez V . Ultrastructural and biochemical analysis of the effects of alendronate on salivary glands of young rats. Arch Oral Biol. 2014; 59(12):1307-11. DOI: 10.1016/j.archoralbio.2014.07.020. View

15.

Cruz L, Assumpcao E, Andrade S, Conrado D, Guterres S, Pohlmann A . Microencapsulation of sodium alendronate reduces drug mucosal damage in rats. Drug Deliv. 2010; 17(4):231-7. DOI: 10.3109/10717541003667830. View

16.

Cardwell C, Abnet C, Cantwell M, Murray L . Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304(6):657-63. PMC: 3513370. DOI: 10.1001/jama.2010.1098. View

17.

Donetti E, Gualerzi A, Sardella A, Lodi G, Carrassi A, Sforza C . Alendronate impairs epithelial adhesion, differentiation and proliferation in human oral mucosa. Oral Dis. 2013; 20(5):466-72. DOI: 10.1111/odi.12154. View

18.

Pozzi S, Marcheselli R, Falorio S, Masini L, Stelitano C, Falcone A . Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. Am J Hematol. 2009; 84(12):850-2. DOI: 10.1002/ajh.21553. View

19.

Garcia-Font M, Curco N, Prat C, Vives P . [Mouth sores caused by alendronate]. Actas Dermosifiliogr. 2009; 100(1):77-8. View

20.

Isaacs J, Shidiak L, Harris I, Szomor Z . Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res. 2010; 468(12):3384-92. PMC: 2974861. DOI: 10.1007/s11999-010-1535-x. View